Adaptive Biotechnologies (NASDAQ:ADPT) Stock: Insider Julie Rubinstein Sells 11,881 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 11,881 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $25.47, for a total transaction of $302,609.07. Following the completion of the sale, the chief operating officer owned 377,802 shares in the company, valued at approximately $9,622,616.94. This trade represents a 3.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Friday, October 30th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.73, for a total transaction of $317,579.13.
• On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.45, for a total transaction of $338,014.45.
• On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.04, for a total value of $309,381.24.
• On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.98, for a total value of $296,787.38.
• On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.05, for a total value of $285,738.05.
• On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total value of $301,896.21.
• On Thursday, October 15th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.61, for a total value of $304,272.41.
• On Tuesday, October 13th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.50, for a total value of $302,965.50.
• On Thursday, October 8th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.66, for a total value of $304,866.46.
• On Monday, October 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $29.19, for a total value of $346,806.39.

Adaptive Biotechnologies Trading Up 3.5%

NASDAQ ADPT opened at $26.71 on Thursday. Adaptive Biotechnologies Corporation has a 12 month low of $12.00 and a 12 month high of $30.74. The stock has a market cap of $4.26 billion, a P/E ratio of -65.15 and a beta of 2.18. The stock’s fifty day moving average price is $26.37 and its 200-day moving average price is $19.76. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.12. The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $71.57 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%. The company’s revenue was down 10.7% on a year-over-year basis. During the same period last year, the company earned $0.06 earnings per share. As a group, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.40 EPS for the current fiscal year.

More Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive reported earnings of $0.02 per share, versus analysts’ expectation of a $0.10-per-share loss. Management also said the company achieved total-company profitability ahead of expectations. Third-quarter 2026 financial results
• Positive Sentiment: Revenue was $83.9 million, exceeding the $71.57 million analyst estimate. Core measurable residual disease (MRD) revenue grew 44%, a strong growth signal for a key business area. Q3 earnings and revenues top estimates
• Neutral Sentiment: COO Julie Rubinstein sold 11,881 shares under a pre-arranged Rule 10b5-1 trading plan and retained 377,802 shares. The planned nature of the sale may make it less meaningful as a signal about near-term business prospects. Insider share sale
• Negative Sentiment: Revenue was still down 10.7% from the year-ago quarter, tempering the strong results versus analyst estimates. The company also reported a negative net margin. Quarterly earnings report

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Adaptive Biotechnologies during the second quarter valued at approximately $324,735,000. Wellington Management Group LLP raised its stake in Adaptive Biotechnologies by 53.2% during the 2nd quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock valued at $126,799,000 after buying an additional 2,053,944 shares during the last quarter. Bank of America Corp DE purchased a new stake in Adaptive Biotechnologies during the 2nd quarter valued at $37,109,000. Principal Financial Group Inc. lifted its holdings in shares of Adaptive Biotechnologies by 9.8% during the 1st quarter. Principal Financial Group Inc. now owns 1,704,887 shares of the company’s stock valued at $23,664,000 after buying an additional 152,378 shares during the period. Finally, Freestone Grove Partners LP purchased a new position in shares of Adaptive Biotechnologies in the 2nd quarter worth $18,912,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. The Goldman Sachs Group started coverage on shares of Adaptive Biotechnologies in a research note on Tuesday, September 29th. They set a “buy” rating and a $35.00 price objective for the company. Piper Sandler raised their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. BTIG Research upped their price objective on Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Tuesday, September 22nd. Guggenheim lifted their target price on Adaptive Biotechnologies from $25.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Finally, National Bank Financial set a $34.00 price target on Adaptive Biotechnologies in a research note on Tuesday, September 22nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $30.06.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.